Aspira Women's Health Inc
NASDAQ:AWH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (100.6), the stock would be worth $2.03 (7 409% upside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.3 | $0.03 |
0%
|
| 3-Year Average | 100.6 | $2.03 |
+7 409%
|
| 5-Year Average | 470.1 | $9.47 |
+34 985%
|
| Industry Average | 2.1 | $0.04 |
+55%
|
| Country Average | 3 | $0.06 |
+127%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
$23.7m
|
/ |
Jan 2025
$9.2m
|
= |
|
|
$23.7m
|
/ |
Dec 2025
$18.3m
|
= |
|
|
$23.7m
|
/ |
Dec 2026
$36.8m
|
= |
|
|
$23.7m
|
/ |
Dec 2027
$82.3m
|
= |
|
|
$23.7m
|
/ |
Dec 2028
$102.9m
|
= |
|
|
$23.7m
|
/ |
Dec 2029
$123.5m
|
= |
|
|
$23.7m
|
/ |
Dec 2030
$145.7m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Aspira Women's Health Inc
NASDAQ:AWH
|
12.2m USD | 1.3 | -1.8 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.5B USD | 15.5 | 56.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
157.7B USD | 3.5 | 25.1 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 5.2 | 37.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
103.9B USD | 3.5 | 22.5 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
85.4B USD | 4.6 | 24 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 7.1 | 44.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 2 | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.7B USD | 10.5 | 42.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.4B USD | 2.7 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.1B USD | 5.6 | 21 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 3 |
| 70th Percentile | 5.3 |
| Max | 4 613 320.1 |
Other Multiples
Aspira Women's Health Inc
Glance View
Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. The company is headquartered in Austin, Texas and currently employs 106 full-time employees. The company went IPO on 2000-09-29. Its products include OVA1 and Overa, OVA1plus, Aspira GenetiX and Aspira Synergy. OVA1 is a blood test that is intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician’s independent clinical, and Overa is intended to maintain OVA1’s high sensitivity. OVA1plus is a reflex test performed for those OVA1 test results that are in the intermediate risk range. Aspira GenetiX is a genetic test for gynecologic cancer risk, with a focus on female reproductive cancers, including breast, ovarian, endometrial, uterine and cervical cancers. Aspira Synergy is an en-suite, cloud-based technology transfer solution that provides an end-to-end solution from specimen collection to a customized white-label report for clinical laboratories to internalize testing of its products.
